SNCA and synucleinopathy: USP13 inhibition may prevent de-ubiquitination of alpha-synuclein and limit its aggregation via the promotion of autophagy and proteasome clearance [1,5]; thus, USP13 inhibitors may provide therapeutic agents in alpha-synucleinopathies [10].